Fenofibrate in Ulcerative Colitis

• Status: Recruiting
• Trial end date: 2025-06-20
• Target enrollment: 0
• Participant gender: All

Summary

Fibrates, which are specific pharmacological agonists of PPARα, have been widely used in the treatment of hypercholesterolemia and hypertriglyceridemia. Apart from their metabolic action, anti-inflammatory properties of fibrates have been described, including inhibition of NF-kappa B signaling and pro-inflammatory cytokine production. 4 Fenofibrate, an important peroxisome proliferator-activated receptor-a (PPAR- α) agonist, is widely used in clinical as a triglyceride (TG)-lowering agent.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tanta University
• Collaborators: Eman Ibrahim Elberri, Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University; Eman Maamoun Ali El-Khateeb, Lecturer of Clinical Pharmacy, Clinical Pharmacy Department, Faculty of Pharmacy, Tanta University; Hend El-Said Abo Mansour, Biochemistry Department, Faculty of Pharmacy, Menoufia University; Monir Hussein Bahgat, Internal Medicine Department (Gastroenterology and Hepatology), Faculty of Medicine, Mansura University
• Treatments: Fenofibrate; Mesalamine

Criteria

Inclusion Criteria:

• Age ≥ 18 years

• Both males and females will be included

• Negative pregnancy test and effective contraception.

• Mild and moderate UC patients diagnosed and confirmed by an endoscope

Exclusion Criteria:

• Breastfeeding

• Significant liver and kidney function abnormalities

• Colorectal cancer patients

• Other inflammatory bowel diseases (CD).

• Patients with severe UC

• Patients taking rectal or systemic steroids

• Patients taking immunosuppressives or biological therapies

• Addiction to alcohol and/or drugs

• Known allergy to the Fenofibrate